MX349239B - Sistema de cest que muestran una sensibilidad independiente de la concentración. - Google Patents

Sistema de cest que muestran una sensibilidad independiente de la concentración.

Info

Publication number
MX349239B
MX349239B MX2013004825A MX2013004825A MX349239B MX 349239 B MX349239 B MX 349239B MX 2013004825 A MX2013004825 A MX 2013004825A MX 2013004825 A MX2013004825 A MX 2013004825A MX 349239 B MX349239 B MX 349239B
Authority
MX
Mexico
Prior art keywords
cest
concentration independent
systems exhibiting
nmr
responsiveness
Prior art date
Application number
MX2013004825A
Other languages
English (en)
Spanish (es)
Other versions
MX2013004825A (es
Inventor
Uggeri Fulvio
Aime Silvio
Delli Castelli Daniela
Terreno Enzo
Livio Longo Dario
Fedeli Franco
Original Assignee
Bracco Imaging Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging Spa filed Critical Bracco Imaging Spa
Publication of MX2013004825A publication Critical patent/MX2013004825A/es
Publication of MX349239B publication Critical patent/MX349239B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
MX2013004825A 2010-11-05 2011-11-04 Sistema de cest que muestran una sensibilidad independiente de la concentración. MX349239B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190161A EP2457594A1 (en) 2010-11-05 2010-11-05 Cest systems exhibiting a concentration independent responsiveness
PCT/EP2011/069406 WO2012059576A1 (en) 2010-11-05 2011-11-04 Cest systems exhibiting a concentration independent responsiveness

Publications (2)

Publication Number Publication Date
MX2013004825A MX2013004825A (es) 2013-06-03
MX349239B true MX349239B (es) 2017-07-18

Family

ID=43530158

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004825A MX349239B (es) 2010-11-05 2011-11-04 Sistema de cest que muestran una sensibilidad independiente de la concentración.

Country Status (11)

Country Link
US (2) US10232060B2 (https=)
EP (2) EP2457594A1 (https=)
JP (2) JP2013542948A (https=)
KR (1) KR20130138807A (https=)
CN (1) CN103260652B (https=)
AU (1) AU2011325112B2 (https=)
CA (1) CA2816948C (https=)
IL (1) IL226123A (https=)
MX (1) MX349239B (https=)
RU (1) RU2605823C2 (https=)
WO (1) WO2012059576A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165766A1 (en) 2013-04-05 2014-10-09 The Trustees Of The University Of Pennsylvania Quantification of in vivo metabolite
KR101653064B1 (ko) * 2014-12-26 2016-09-09 에스티팜 주식회사 가도부트롤의 제조방법
WO2016123446A1 (en) * 2015-01-30 2016-08-04 The Johns Hopkins University Label-free mr imaging of tumor malignancy
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
HRP20210061T1 (hr) * 2015-12-10 2021-03-05 Bracco Imaging S.P.A Dimerna kontrastna sredstva
EP3394627B1 (en) * 2015-12-23 2020-06-03 Bracco Imaging S.p.A Ratiometric pulsed cest imaging
ES2814555T3 (es) 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CN108047151B (zh) * 2018-01-03 2020-08-04 广州康瑞泰药业有限公司 一种高收率钆布醇的制备方法
KR102934987B1 (ko) 2018-11-23 2026-03-09 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
EP3897749A1 (en) 2018-12-18 2021-10-27 Bracco Imaging SPA Pharmaceutical compositions comprising gd-complexes and polyarylene additives
US20200397924A1 (en) * 2019-01-28 2020-12-24 Hubei Tianshu Pharmaceutical Co., Ltd Preparation method of intermediate of gadolinium-based ionic contrast agent and use thereof
US12529739B2 (en) * 2022-07-26 2026-01-20 Canon Medical Systems Corporation pH calculating apparatus, magnetic resonance imaging apparatus, and pH calculating method
CN120609858A (zh) * 2025-05-30 2025-09-09 中国科学院精密测量科学与技术创新研究院 镧系金属配合物作为31p cest高场造影剂在识别atp中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
GB9504910D0 (en) 1995-03-10 1995-04-26 Nycomed Imaging As Compounds
US6963769B1 (en) 1999-04-21 2005-11-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for enhancing contrast produced by MRI
WO2002043775A2 (en) * 2000-11-20 2002-06-06 GODFREY, Cullen, M. Paramagnetic metal ion-based macrocyclic contrast agents
EP1331012A1 (en) * 2002-01-29 2003-07-30 BRACCO IMAGING S.p.A. Responsive paramagnetic MRI contrast agents
EP1466629A1 (en) * 2003-04-11 2004-10-13 BRACCO IMAGING S.p.A. Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for "CEST" applications
US20070292354A1 (en) * 2004-09-23 2007-12-20 Guerbet Contrast Agents Encapsulating Systems for Cest Imaging
RU2446829C2 (ru) * 2006-06-09 2012-04-10 Конинклейке Филипс Электроникс Н.В. Устранение зависимости от концентрации контрастного агента в мрт
US20100247445A1 (en) * 2007-12-07 2010-09-30 Koninklijke Philips Electronics N.V. Polymeric drug carrier for image-guided delivery
EP2067485A1 (en) * 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement

Also Published As

Publication number Publication date
US20130195768A1 (en) 2013-08-01
RU2013125778A (ru) 2014-12-10
US10328162B1 (en) 2019-06-25
EP2457594A1 (en) 2012-05-30
CN103260652A (zh) 2013-08-21
EP2635311A1 (en) 2013-09-11
AU2011325112B2 (en) 2016-03-31
IL226123A (en) 2016-02-29
MX2013004825A (es) 2013-06-03
RU2605823C2 (ru) 2016-12-27
IL226123A0 (en) 2013-06-27
JP2017078080A (ja) 2017-04-27
WO2012059576A1 (en) 2012-05-10
CN103260652B (zh) 2016-10-12
CA2816948A1 (en) 2012-05-10
AU2011325112A1 (en) 2013-05-02
JP6542748B2 (ja) 2019-07-10
US20190209713A1 (en) 2019-07-11
US10232060B2 (en) 2019-03-19
CA2816948C (en) 2016-04-05
KR20130138807A (ko) 2013-12-19
EP2635311B1 (en) 2017-08-16
JP2013542948A (ja) 2013-11-28

Similar Documents

Publication Publication Date Title
MX349239B (es) Sistema de cest que muestran una sensibilidad independiente de la concentración.
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
CY1119345T1 (el) Μακροκυκλικες ενωσεις ως αναστολεις κινασης trk
GEAP202014664A (en) New gadolinium chelate compounds for use in magnetic resonance imaging
BR112014017169A8 (pt) máquina de bebidas com módulo removível
PT2647707T (pt) Agente terapêutico indutor de toxicidade
ZA201206580B (en) Spirocyclic compounds and thier use as therapeutic agents and diagnostic probes
ECSP12012213A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos ? 2 y como antagonistas muscarinicos m3
ECSP14013327A (es) Compuestos con actividad nematicida
MX382868B (es) Composiciones que comprenden polietilenglicol y ascorbato.
CR20130239A (es) Compuestos de triazolopiridina
MX2012007041A (es) Quelados de manganeso y su uso como agentes de contraste en elaboracion de imagen de resonancia magnetica (mri).
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
MX340607B (es) Moduladores de la fosfodiesterasa 10 (pde 10).
MX2012000097A (es) Nuevos derivados de 2,3-dihidro-1h-imidazo {1,2-a} pirimidin-5-ona, su preparacion y su uso en farmaceutica.
WO2012158467A3 (en) Indicators for detecting the presence of metabolic by-products from microorganisms
MX2011012688A (es) Composicion de sal no aglutinante, proceso de preparacion y uso de la misma.
MX360027B (es) Derivados de monoterpeno de calcona o dihidrocalcona y su uso como agentes despigmentantes.
GB2517345A (en) Anthracenyl-tetralactam macrocycles and their use in detecting a target saccharide
IN2014DN03197A (https=)
EP2587997A4 (en) FABRIC INDICATOR DETERMINATION
IN2015DN00085A (https=)
IT1402938B1 (it) Attrezzatura per banchi di prova dell'impianto frenante di veicoli

Legal Events

Date Code Title Description
FG Grant or registration